Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2025	Sep. 30, 2024
Current assets:
Cash, cash equivalents and restricted cash	$ 185,709	$ 102,685
Accounts receivable	2,365	0
Available-for-sale securities, at fair value	911,700	578,276
Prepaid expenses	23,769	9,537
Other current assets	11,677	4,973
Total current assets	1,135,220	695,471
Property, plant and equipment, net	384,803	386,032
Intangible assets, net	7,711	8,562
Right-of-use assets	44,452	45,255
Other assets	1,312	4,482
Total Assets	1,573,498	1,139,802
Current liabilities:
Accounts payable	9,980	11,388
Accrued expenses	78,450	63,017
Accrued payroll and benefits	16,613	21,989
Lease liabilities	6,782	6,342
Deferred revenue	43,268	0
Credit facility	65,000	0
Other liabilities	448	432
Total current liabilities	220,541	103,168
Long-term liabilities:
Lease liabilities, net of current portion	107,529	111,027
Liability related to the sale of future royalties	352,276	341,361
Credit facility, net of current portion	208,927	393,183
Total long-term liabilities	668,732	845,571
Commitments and contingencies (Note 7)
Noncontrolling interest and stockholders’ equity:
Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 138,062 and 124,376 shares	230	217
Additional paid-in capital	2,106,864	1,806,000
Accumulated other comprehensive income	4,390	4,750
Accumulated deficit	(1,428,163)	(1,625,523)
Total Arrowhead Pharmaceuticals, Inc. stockholders’ equity	683,321	185,444
Noncontrolling interest	904	5,619
Total noncontrolling interest and stockholders’ equity	684,225	191,063
Total Liabilities, Noncontrolling Interest and Stockholders’ Equity	$ 1,573,498	$ 1,139,802